The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
18
ICON Development Solutions
Omaha, Nebraska, United States
Number of patients with adverse events
Measurement of safety laboratories, ECGs, vitals signs and physical exams
Time frame: 8 days
Sodium levels in stool and urine
Pharmacodynamic activity
Time frame: 8 days
Plasma drug concentration to calculate AUC
Pharmacokinetics
Time frame: 8 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.